FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

BIOTECH

FDA's Sarepta rejection is rooted in the past, and will weigh on its future
By Adam Feuerstein

You can read more about the FDA’s denial of Vyondys 53 here, but read on for some additional thoughts, analyses, and lingering questions for investors trying to figure out what it all means for Sarepta moving forward.

READ MORE